Skip to main content
Top
Published in: Medical Oncology 4/2012

01-12-2012 | Original Paper

Correlation of LAPTM4B polymorphisms with gallbladder carcinoma susceptibility in Chinese patients

Authors: Hua Yang, Guojun Zhai, Xiaoxu Ji, Fuxia Xiong, Jing Su, Michael A. McNutt

Published in: Medical Oncology | Issue 4/2012

Login to get access

Abstract

Gallbladder carcinoma (GBC) is a malignancy with an extremely poor prognosis. In order to improve the survival rate, identification of new susceptibility risk factors is of importance. Here, we report findings on the novel cancer-related gene lysosomal protein transmembrane 4 beta (LAPTM4B) that has two alleles designated LAPTM4B*1 and LAPTM4B*2. Allele *1 differs from allele *2 in that it contains one copy of a 19-bp sequence, whereas this sequence is duplicated in exon 1 of allele *2. This study aimed to investigate the relationship of LAPTM4B allelic variation and GBC susceptibility. LAPTM4B genotype was analyzed in 155 healthy individuals and 91 GBC patients by PCR, and the genotypic distribution of LAPTM4B was analyzed with the chi-squared test. The frequency of allele *2 was 37.9 and 24.8% in the GBC and the control groups, respectively, representing a significant difference between these two groups (P < 0.001). LAPTM4B allele *2 may be a risk factor associated with genetic susceptibility to GBC.
Literature
1.
go back to reference Wood R, Fraser LA, Brewster DH, et al. Epidemiology of gallbladder cancer and trends in cholecystectomy rates in Scotland, 1968–1998. Eur J Cancer. 2003;39:2080–6.PubMedCrossRef Wood R, Fraser LA, Brewster DH, et al. Epidemiology of gallbladder cancer and trends in cholecystectomy rates in Scotland, 1968–1998. Eur J Cancer. 2003;39:2080–6.PubMedCrossRef
2.
go back to reference Diamantis I, Karamitopoulou E, Perentes E, et al. p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival. Hepatology. 1995;22:774–9.PubMedCrossRef Diamantis I, Karamitopoulou E, Perentes E, et al. p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival. Hepatology. 1995;22:774–9.PubMedCrossRef
3.
go back to reference Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 1995;75:171–90.PubMedCrossRef Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 1995;75:171–90.PubMedCrossRef
4.
go back to reference Abi-Rached B, Neugut AI. Diagnostic and management issues in gallbladder carcinoma. Oncology. 1995;9:19–24.PubMed Abi-Rached B, Neugut AI. Diagnostic and management issues in gallbladder carcinoma. Oncology. 1995;9:19–24.PubMed
5.
go back to reference Hui AM, Li X, Shi YZ, et al. Cyclin D1 overexpression is a critical event in gallbladder carcinogenesis and independently predicts decreased survival for patients with gallbladder carcinoma. Clin Cancer Res. 2000;6:4272–7.PubMed Hui AM, Li X, Shi YZ, et al. Cyclin D1 overexpression is a critical event in gallbladder carcinogenesis and independently predicts decreased survival for patients with gallbladder carcinoma. Clin Cancer Res. 2000;6:4272–7.PubMed
6.
go back to reference Hui AM, Li X, Shi YZ, et al. p27(Kip1) expression in normal epithelia, precancerous lesions, and carcinomas of the gallbladder: association with cancer progression and prognosis. Hepatology. 2000;31:1068–72.PubMedCrossRef Hui AM, Li X, Shi YZ, et al. p27(Kip1) expression in normal epithelia, precancerous lesions, and carcinomas of the gallbladder: association with cancer progression and prognosis. Hepatology. 2000;31:1068–72.PubMedCrossRef
7.
go back to reference Singh MK, Chetri K, Pandey UB, et al. Mutational spectrum of K-ras oncogene among Indian patients with gallbladder cancer. J Gastroenterol Hepatol. 2004;19:916–21.PubMedCrossRef Singh MK, Chetri K, Pandey UB, et al. Mutational spectrum of K-ras oncogene among Indian patients with gallbladder cancer. J Gastroenterol Hepatol. 2004;19:916–21.PubMedCrossRef
8.
go back to reference Shao G, Zhou R, Zhang Q, et al. Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene. 2003;22:5060–9.PubMedCrossRef Shao G, Zhou R, Zhang Q, et al. Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene. 2003;22:5060–9.PubMedCrossRef
9.
go back to reference Lee HM, Zhang H, Schulz V, et al. Downstream targets of HOXB4 in a cell line model of primitive hematopoietic progenitor cells. Blood. 2010;116:720–30.PubMedCrossRef Lee HM, Zhang H, Schulz V, et al. Downstream targets of HOXB4 in a cell line model of primitive hematopoietic progenitor cells. Blood. 2010;116:720–30.PubMedCrossRef
10.
go back to reference Yang H, Xiong F, Wei X, et al. Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer Lett. 2010;294:236–44.PubMedCrossRef Yang H, Xiong F, Wei X, et al. Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer Lett. 2010;294:236–44.PubMedCrossRef
11.
go back to reference Zhou L, He X, Yu J, et al. Expression of LAPTM4B in gallbladder carcinoma cells: the role in invasive potential. Hepatogastroenterology. 2010;57:207–11.PubMed Zhou L, He X, Yu J, et al. Expression of LAPTM4B in gallbladder carcinoma cells: the role in invasive potential. Hepatogastroenterology. 2010;57:207–11.PubMed
12.
go back to reference Yang H, Xiong F, Qi R, et al. LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma. J Surg Oncol. 2010;101:363–9.PubMedCrossRef Yang H, Xiong F, Qi R, et al. LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma. J Surg Oncol. 2010;101:363–9.PubMedCrossRef
13.
go back to reference Yang H, Xiong F, Lin M, et al. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010;136:275–81.PubMedCrossRef Yang H, Xiong F, Lin M, et al. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010;136:275–81.PubMedCrossRef
14.
go back to reference Meng F, Yin M, Song H, et al. LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma. Int J Gynecol Cancer. 2010;20:745–50.PubMedCrossRef Meng F, Yin M, Song H, et al. LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma. Int J Gynecol Cancer. 2010;20:745–50.PubMedCrossRef
15.
go back to reference Meng F, Luo C, Hu Y, et al. Overexpression of LAPTM4B-35 in cervical carcinoma: a clinicopathologic study. Int J Gynecol Pathol. 2010;29:587–93.PubMedCrossRef Meng F, Luo C, Hu Y, et al. Overexpression of LAPTM4B-35 in cervical carcinoma: a clinicopathologic study. Int J Gynecol Pathol. 2010;29:587–93.PubMedCrossRef
16.
go back to reference Yin M, Xu Y, Lou G, et al. LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis. Int J Cancer. 2011;129:629–35.PubMedCrossRef Yin M, Xu Y, Lou G, et al. LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis. Int J Cancer. 2011;129:629–35.PubMedCrossRef
17.
go back to reference Li Y, Zou L, Li Q, et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med. 2010;16:214–8.PubMedCrossRef Li Y, Zou L, Li Q, et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med. 2010;16:214–8.PubMedCrossRef
18.
go back to reference Zhou L, He X, Yu J, et al. Overexpression of LAPTM4B promotes growth of gallbladder carcinoma cells in vitro. Am J Surg. 2010;199:515–21.PubMedCrossRef Zhou L, He X, Yu J, et al. Overexpression of LAPTM4B promotes growth of gallbladder carcinoma cells in vitro. Am J Surg. 2010;199:515–21.PubMedCrossRef
19.
go back to reference Yang Y, Yang H, McNutt MA, et al. LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma. Oncol Rep. 2008;20:1077–83.PubMed Yang Y, Yang H, McNutt MA, et al. LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma. Oncol Rep. 2008;20:1077–83.PubMed
20.
go back to reference Zhou L, He X, Cui Q, et al. Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer Lett. 2008;264:209–17.PubMedCrossRef Zhou L, He X, Cui Q, et al. Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer Lett. 2008;264:209–17.PubMedCrossRef
21.
go back to reference Zhou L, He X, Chen J, et al. Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma. Eur J Cancer. 2007;43:809–15.PubMedCrossRef Zhou L, He X, Chen J, et al. Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma. Eur J Cancer. 2007;43:809–15.PubMedCrossRef
22.
go back to reference Liu X, Xiong F, Wei X, et al. LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells. Cancer Sci. 2009;100:2335–40.PubMedCrossRef Liu X, Xiong F, Wei X, et al. LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells. Cancer Sci. 2009;100:2335–40.PubMedCrossRef
Metadata
Title
Correlation of LAPTM4B polymorphisms with gallbladder carcinoma susceptibility in Chinese patients
Authors
Hua Yang
Guojun Zhai
Xiaoxu Ji
Fuxia Xiong
Jing Su
Michael A. McNutt
Publication date
01-12-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0173-4

Other articles of this Issue 4/2012

Medical Oncology 4/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.